Previous 10 | Next 10 |
ATLANTA, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announc...
Alimera Sciences ( NASDAQ: ALIM ) said on Thursday a post-hoc analyses from a Phase 4 study showed that median treatment frequency in diabetic macular edema patients treated with its therapy Iluvien 0.19 mg was lower than from patients on other regimens. Iluvien provid...
ATLANTA, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced t...
ATLANTA, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces t...
Alimera Sciences ( NASDAQ: ALIM ) on Tuesday said it had been granted reimbursement for its Iluvien injection for the treatment of uveitis, a type of eye inflammation, in Ireland. ALIM said the reimbursement was granted to the its Ireland-based European unit by the Health ...
ATLANTA, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announces ...
ATLANTA, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces th...
ATLANTA, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announced to...
Alimera Sciences ( NASDAQ: ALIM ) on Tuesday said it had been granted reimbursement for its Iluvien injection for the treatment of uveitis, a type of eye inflammation, in Portugal. ALIM said the reimbursement was granted by Portugal's National Authority of Medicines and He...
Reimbursement granted with no restrictions to the label Alimera to begin selling later in Q3 ATLANTA, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to...
News, Short Squeeze, Breakout and More Instantly...
Alimera Sciences Inc. Company Name:
ALIM Stock Symbol:
NASDAQ Market:
Alimera Sciences Inc. Website:
2024-07-07 16:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, NY / ACCESSWIRE / July 3, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Perficient, Inc. (NASDAQ:PRFT)'s sal...
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Alimera Sciences, Inc. (NASDAQ:ALIM)'...